[Featured Stock] Jinwon Life Sciences Gains Attention as Omicron-Related Stock
On the 23rd, Jungbu Market in Jung-gu, Seoul, was quiet. There have been a total of 199 confirmed COVID-19 cases related to Jungbu Market. The Seoul Metropolitan Government tested a total of 687 people, including contacts. Excluding the initial confirmed case, 198 tested positive, 451 tested negative, and the rest are awaiting results. Workers at the facility shared restrooms and other common areas, and it was difficult for employees of nearby stores to maintain social distancing. It was confirmed that some confirmed cases continued to work even after showing COVID-19 symptoms. Photo by Moon Ho-nam munonam@
View original image[Asia Economy Reporter Hwang Junho] On the 3rd, the stock price of Genexine, a biopharmaceutical manufacturer, is soaring.
As of 10:52 AM on the same day, Genexine's stock price is trading at 23,050 KRW, up 16.12% compared to the previous day.
Hot Picks Today
Who Is the Twenty-Something Man Who Blew $800,000 a Day on Ferraris and Hermes Bags in Nightclubs?
- "The Flavor That Won Over Ahn Yujin" Now at Convenience Stores... 500,000 Units Sold Out in 5 Days, What's Behind the Craze?
- Faster Than Her Mother... Stranger Dramatically Saves Child Running Into Traffic
- Asked ‘Where to Invest $10,000’: “Water, Luxury Goods, and Korea”…Foreign Experts Say “Still Undervalued”
- "Never Seen Anything Like This in My Life, Shocked" Feces Discovered in the Middle of Jamsil Baseball Stadium Passage
Genexine is a COVID-19 vaccine-related stock. According to the industry, Innovio, which shares research and development projects with Genexine's subsidiary CGXI, has reportedly started preclinical development of a specific DNA vaccine candidate related to Omicron.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
